| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Cell Failure and Diabetes
Department of Biological Chemistryand Internal Medicine, and Howard Hughes Medical Institute, The University of Michigan Medical Center, Ann Arbor, MI 48109
* To whom correspondence should be addressed. E-mail: scheuner{at}umich.edu.
The endoplasmic reticulum (ER) is the entry site into the secretory pathway for newly synthesized proteins destined for the cell surface or released into the extracellular milieu. The study of protein folding and trafficking within the ER is an extremely active area of research that has provided novel insights into many disease processes. Cells have evolved mechanisms to modulate the capacity and quality of the ER protein-folding machinery to prevent the accumulation of unfolded or misfolded proteins. These signaling pathways, collectively termed the unfolded protein response (UPR), detect the accumulation of unfolded and misfolded proteins in the ER lumen through three ER transmembrane sensors, IRE1
, PERK, and ATF6. The UPR sensors signal a transcriptional response to expand the ER folding capacity and to limit the rate of mRNA translation to reduce the client protein load. Recent genetic and biochemical evidence in both humans and mice supports a requirement for the UPR to preserve ER homeostasis and prevent the beta cell failure that may be fundamental in the etiology of diabetes. Chronic or overwhelming ER stress stimuli associated with metabolic syndrome can disrupt protein folding in the ER, reduce insulin production, and activate cell death pathways. Therapeutic interventions to prevent polypeptide-misfolding and/or UPR-induced cell death have the potential to improve
-cell function and/or survival in the treatment of diabetes.
-cell
diabetes
This article has been cited by other articles:
![]() |
V. Poitout and R. P. Robertson Glucolipotoxicity: Fuel Excess and {beta}-Cell Dysfunction Endocr. Rev., May 1, 2008; 29(3): 351 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Haataja, T. Gurlo, C. J. Huang, and P. C. Butler Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis Endocr. Rev., May 1, 2008; 29(3): 303 - 316. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |